Welcome to our dedicated page for Petros Pharmaceuticals SEC filings (Ticker: PTPI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Petros Pharmaceuticals, Inc. filings document its public-company reporting status, governance actions and corporate-status changes. The record includes Form 8-K disclosures on restricted stock unit grants to directors and officers, Nasdaq delisting notices, continued OTCID Basic Market trading under PTPI, and a Form 25 covering removal of the company’s common stock from Nasdaq listing and Section 12(b) registration.
Other filings address annual-report timing through a Form 12b-25 notification and operating matters tied to Metuchen Pharmaceuticals, including termination of the Stendra license arrangement and related commercialization rights. These disclosures frame the company’s capital structure, reporting obligations, incentive compensation and subsidiary-related business changes.
Petros Pharmaceuticals, Inc. director Joshua Silverman reported a new equity award in the company’s common stock. On 01/02/2026, he received 4,375,000 restricted stock units (RSUs) at a price of $0, reflecting a compensatory grant. Half of these RSUs vested on the grant date, and the remaining half will vest on the six‑month anniversary of the grant, provided he continues providing services to the company.
Each RSU represents the right to receive one share of common stock with a par value of $0.0001 per share. Following this transaction, Silverman beneficially owned 4,415,450 shares of Petros Pharmaceuticals common stock directly. The reported amounts have been adjusted to reflect the company’s 1‑for‑25 reverse stock split of its common stock that became effective at 4:05 p.m. New York time on April 30, 2025.
Petros Pharmaceuticals, Inc. reported that its Board of Directors approved new equity awards for key directors and an executive officer. Effective January 2, 2026, the company granted a total of 7,250,000 restricted stock units (RSUs), including 4,375,000 RSUs to Chairman Joshua Silverman, 1,875,000 RSUs to director Bruce Bernstein, 500,000 RSUs to President and Chief Commercial Officer Fady Boctor, and 500,000 RSUs to director Wayne Walker. Each RSU gives the holder the right to receive one share of Petros common stock. Half of each grant vested on the grant date, with the remaining half scheduled to vest six months later, as long as the recipient continues providing services to the company. These RSU awards were issued outside the company’s 2020 Omnibus Incentive Compensation Plan and are governed by Petros’s standard Restricted Stock Unit Agreement.
Petros Pharmaceuticals, Inc. reported an equity award to a director on a Form 4. On 01/02/2026, a director received 500,000 restricted stock units (RSUs) of Petros Pharmaceuticals common stock at a stated price of $0 per unit. According to the filing, 50% of the RSUs vested on the grant date and the remaining 50% will vest on the six-month anniversary of the grant date, as long as the director continues providing services to the company on that vesting date. Each RSU corresponds to one share of common stock. Following this grant, the director is reported to beneficially own 506,333 shares of Petros Pharmaceuticals common stock. The filing notes that these share amounts have been adjusted for the company’s 1-for-25 reverse stock split that became effective on April 30, 2025.
Petros Pharmaceuticals, Inc. reported that a director acquired additional equity through a stock-based compensation grant. On 01/02/2026, the reporting person received 1,875,000 Restricted Stock Units (RSUs) of Petros common stock at a price of $0 per unit, recorded as an acquisition. Following this grant, the director beneficially owns 1,887,334 shares of common stock in direct ownership.
The filing explains that 50% of the RSUs vested on the grant date and the remaining 50% will vest on the six-month anniversary of the grant, provided the director is still providing services to the company at that time. Each RSU converts into one share of common stock. The share amounts in the filing have been adjusted to reflect the company’s previously effected 1-for-25 reverse stock split of its common stock.
Petros Pharmaceuticals, Inc. (PTPI) has had its common stock removed from listing and registration on the Nasdaq Stock Market LLC. Nasdaq filed a Form 25 under Section 12(b) of the Securities Exchange Act of 1934, certifying that it complied with its rules and the requirements of 17 CFR 240.12d2-2(b) to strike this class of securities from listing and/or registration. The filing is signed on behalf of Nasdaq by a hearings advisor, confirming Nasdaq’s action to delist PTPI’s common stock from the exchange.
Petros Pharmaceuticals (PTPI) filed its Q3 2025 10‑Q. The company exited legacy products, recorded a $6.97 million gain from assigning subsidiaries and a Vivus settlement, and reported nine‑month net income of $2.25 million. From continuing operations, it posted a loss of $4.16 million; large preferred-related deemed dividends and warrant items drove a nine‑month loss per share of $1.95.
Liquidity remains tight: cash was $6,070,266 and working capital was $3.4 million as of September 30, 2025, with substantial doubt about continuing as a going concern. Stockholders’ equity improved to $3,368,087 from a deficit at year‑end 2024. A February 2025 financing raised $9.6 million gross (about $8.5 million net). The company effected a 1‑for‑25 reverse split on April 30, 2025, and its common stock was delisted from Nasdaq and now trades on the OTC Market.
Capital structure shifted materially: investors exercised Series B warrants via alternative cashless exercise for 39,208,828 shares during the period. Common shares outstanding were 42,284,502 at September 30, 2025, and 42,372,260 as of November 12, 2025.
Petros Pharmaceuticals (PTPI) reported a Nasdaq delisting process. Nasdaq notified the company on November 3, 2025 that it intends to announce the delisting of Petros’ common stock. Nasdaq will file a Form 25 to deregister the stock under Section 12(b), and the delisting becomes effective ten days after that filing.
The stock was suspended from The Nasdaq Capital Market on May 22, 2025 and has traded on the OTCID Basic Market under “PTPI” since July 1, 2025. Petros states trading on the OTCID will continue without disruption, and the company will remain subject to reporting obligations under Sections 13 and 15(d) of the Exchange Act.